Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular diseases

This page shows the latest cardiovascular diseases news and features for those working in and with pharma, biotech and healthcare.

AZ’s Sean Bohen to exit after business overhaul; report

AZ’s Sean Bohen to exit after business overhaul; report

company restructured around two divisions – cancer and biopharmaceuticals including cardiovascular, diabetes and respiratory drugs. ... Immunocore, and Ludovic Helfgott – AZ’s head of cardiovascular and metabolic diseases – is set to join Novo

Latest news

  • Roche enters NASH race with deal to buy Jecure Roche enters NASH race with deal to buy Jecure

    Feldstein – sits apart from rival therapies and could have applications beyond NASH in other inflammatory disorders gout including inflammatory bowel disease and cardiovascular diseases. ... We’re excited to combine Jecure’s portfolio with our

  • Boston Scientific makes $4.2bn play for UK’s BTG Boston Scientific makes $4.2bn play for UK’s BTG

    The deal bolsters Boston Scientific’s portfolio with interventional medicine products for cancer and cardiovascular diseases, which fit in well with the US company’s current product range, as well as ... Boston Scientific is arguably best known for

  • Alexion targets RNAi with $637m Dicerna deal Alexion targets RNAi with $637m Dicerna deal

    The drug technology platform produces compounds that inhibit complement activation, and it can be applied across multiple therapeutic areas, including cardiovascular diseases, viral infectious disease and liver diseases. ... With Soliris, Alexion has

  • AI company Sensyne raises £60m in IPO AI company Sensyne raises £60m in IPO

    According to the prospectus, it’s also working on additional digital health software products in respiratory, cardiovascular, neurological and immunological diseases as well as cancer.

  • AZ makes gene therapy move with 4DMT alliance AZ makes gene therapy move with 4DMT alliance

    It also has a long-running collaboration with Moderna seeking messenger RNA drugs for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology, and is ... Last year, AZ also paid 25m upfront in a research deal

More from news
Approximately 5 fully matching, plus 90 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    He says the company is “very confident” of sustaining growth in China, and says its broad portfolio of medicines across oncology, respiratory and cardiovascular, metabolic and renal will help it achieve ... diseases, cardiovascular diseases,

  • Finding the patient voice Finding the patient voice

    rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.

  • Deal Watch December 2016 Deal Watch December 2016

    1, 850. Bicycle (UK). AstraZeneca (UK). Licence collaboration. Bicycle platform: small molecules with antibody specificity for targets in respiratory, cardiovascular and metabolic diseases. ... 320. Evotec (Germany). Celgene (US). Discovery collaboration.

  • A healthy challenge A healthy challenge

    Vytenis told PME he is “very concerned” about the rising burden of chronic non-communicable diseases, such as cardiovascular diseases, cancer and type 2 diabetes. ... The risk of developing these diseases is very much increased due to some of our

  • Cost containment and the German market Cost containment and the German market

    Apart from growing revenues from innovative drugs, the sales volumes of medicine for highly prevalent and chronic diseases like cardiovascular indications are expected to increase due to the demographic development. ... Biopharmaceuticals have become

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

  • Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

    Under Bahija’s leadership, MedImmune significantly boosted its pipeline, expanding from 40 to more than 130 molecules in research and development targeting cancer; respiratory, inflammation, and autoimmunity; cardiovascular, renal and metabolic;

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    Prior to this, Dr Lee was therapeutic area head for cardiovascular, metabolic, respiratory and infectious disease programmes at Genentech. ... Meanwhile, Dr Tripuraneni (pictured left) brings over 10 years of medical affairs expertise in a variety of

  • Cardio3 BioSciences appoints Warren Sherman chief medical officer Cardio3 BioSciences appoints Warren Sherman chief medical officer

    therapy and other treatments for cardiovascular diseases.”. ... for the further development of Cardio3 BioSciences' future projects in regenerative therapies and cardiovascular diseases.”.

  • Pfizer appoints diabetes expert Morris Birnbaum Pfizer appoints diabetes expert Morris Birnbaum

    He takes up post as chief scientific officer for cardiovascular and metabolic diseases. ... Pfizer has appointed prominent academic Dr Morris Birnbaum as chief scientific officer for its research into cardiovascular and metabolic diseases.

  • INC Research appoints Dr Martin Sullivan INC Research appoints Dr Martin Sullivan

    INC Research has appointed Dr Martin Sullivan as its new executive director for cardiovascular medicine. . ... Sally Osmond, general manager of cardiovascular and endocrinology clinical development at INC Research, said: "The prevalence of

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics